Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 14/20 | 0.48 |
| ▸ | MC5R | P33032 | 14/20 | 0.48 |
| ▸ | MC3R | P41968 | 13/20 | 0.48 |
| ▸ | MC1R | Q01726 | 13/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008924 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL1324396 | 0.78 | EPHX1 (0.50) | MC4RMC5RMC3RMC1R | |
| SCHEMBL14040579 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL6623800 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19FKBP1A | |
| SCHEMBL3216213 | 0.74 | KDM1A (0.61) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL6507786 | 0.74 | STS (0.48) | SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL31382324 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 | |
| SCHEMBL19789927 | 0.73 | MC4R (0.59) | MC4RMC5RMC3RMC1R | |
| SCHEMBL7418029 | 0.73 | — | — | |
| SCHEMBL18084812 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AHTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414057-B2 | Piperazine urea derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2008039418-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| US-6458790-B2 | DIETETICS; ANTIDABETIC AGENTS; SEXUAL DISRDERS | MERCK & CO., INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MERCK SHARP & DOHME CORP. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253744-A1 | Acylated piperidine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | SMN1; SMN2 2051/4885NPC1 2960/4885RAB9A 2286/4885 |
| US-20020019523-A1 | Substituted piperidines as melanocortin receptor agonists | MC4R, MC5R, MC3R | SMN1; SMN2 1936/4885NPC1 3358/4885RAB9A 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.